Imetelstat

Summary

Imetelstat (CHEMBL2107856) is a phase-3 clinical-stage unknown (ATC L01XX80); indicated across 10 conditions including primary myelofibrosis and neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• ATC class: L01XX80
• Indications: 10 conditions
• Clinical trials: 18

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107856
Name	Imetelstat
Type	Unknown
Max phase	3
ATC	L01XX80

Also known as: GRN-163L, GRN163L, Imetelstat, IMETELSTAT

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

10 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
primary myelofibrosis	3	MONDO:0009692	MONDO:0044903
neoplasm	3	MONDO:0005070	EFO:0000616
myelodysplastic syndrome	2	MONDO:0018881	EFO:0000198
essential thrombocythemia	2	MONDO:0005029	EFO:0000479
plasma cell myeloma	2	MONDO:0009693	EFO:0001378
acquired polycythemia vera	2	MONDO:0009891	EFO:0002429
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
neuroblastoma	1	MONDO:0005072	EFO:0000621
lymphoma	1	MONDO:0005062	EFO:0000574
breast neoplasm	1	MONDO:0021100	MONDO:0007254

Clinical trials

Total trials: 18.

Phase distribution

Phase	Trials
PHASE1	10
PHASE2	6
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04576156	PHASE3	ACTIVE_NOT_RECRUITING	A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
NCT07549451	PHASE2	NOT_YET_RECRUITING	Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms
NCT01137968	PHASE2	COMPLETED	Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)
NCT01242930	PHASE2	COMPLETED	Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma
NCT01243073	PHASE2	COMPLETED	Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera
NCT01731951	PHASE2	COMPLETED	Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
NCT02426086	PHASE2	COMPLETED	Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor
NCT06247787	PHASE1	RECRUITING	A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
NCT07320235	PHASE1	RECRUITING	Imetelstat Combinations in Relapsed AML
NCT00124189	PHASE1	COMPLETED	Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)
NCT00310895	PHASE1	COMPLETED	Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies
NCT00510445	PHASE1	COMPLETED	Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer
NCT00594126	PHASE1	COMPLETED	Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma
NCT00718601	PHASE1	COMPLETED	Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma
NCT00732056	PHASE1	COMPLETED	A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer
NCT01568632	PHASE1	WITHDRAWN	Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma
NCT01916187	PHASE1	WITHDRAWN	Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma
NCT05937568	Not specified	APPROVED_FOR_MARKETING	Expanded Access for Treatment With Imetelstat

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).